English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduMicroRNA (miRNA) can be used as a biomarker to predict which patients are likely to face breast cancer recurrence and mortality, according to study results published online ahead of print in the Journal of the American College of Surgeons (JACS).
Tag: Cancer Research
Extracellular Viscosity Linked to Cancer Spread
New research findings show how higher viscosity, or resistance to flow, of the extracellular fluid that surrounds cells enables cancer cells to migrate more rapidly from a primary tumor to other sites in the body.
Cleveland Clinic Receives $12 Million NIH Grant to Investigate Use of Inflammatory Cytokines in Personalized Cancer Treatments
Cleveland Clinic’s Lerner Research Institute was awarded a five-year $12 million grant by the National Cancer Institute, part of the National Institutes of Health, to define how cytokines – proteins produced during immune response – regulate inflammation and interact with cells and molecules surrounding tumors.
Children with resistant leukemia given CRISPR-edited T cells: Phase 1 study results reported
Researchers at Great Ormond Street Hospital for Children (GOSH) and UCL Great Ormond Street Institute of Child Health (UCL GOS ICH) have used CRISPR/Cas9 technology to engineer donor T cells to try to treat seriously ill children with resistant leukemia, who had otherwise exhausted all available therapies.
University of Kentucky researchers create new cancer fighting compound
A University of Kentucky Markey Cancer Center researcher’s team developed new chemical compounds that show promise as a potential anticancer therapy to treat aggressive tumors. The study led by Samuel G. Awuah, Ph.D., was published in Chemical Communications with Adedamola Arojojoye, a graduate student in Awuah’s lab as the paper’s first author.
Radiation-hormone therapy combination may slow growth of oligometastatic prostate cancer
A new study offers a new option to patients with oligometastatic prostate cancer who want relief from hormone therapy without compromising the risk of their disease spreading. In the study, patients who received radiation in addition to intermittent hormone therapy lived longer without their disease progressing, and they were able to take longer breaks from the drug treatments. Results of the phase II trial (EXTEND; NCT03599765) will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.
Adding radiation to systemic therapy extends overall survival for patients with advanced liver cancer
Adding radiation therapy to systemic therapy for patients with advanced liver cancer can extend overall survival and delay tumor progression without compromising patients’ quality of life, a randomized phase III clinical trial shows.
Lower prostate cancer screening rates associated with subsequent increase in advanced cancers
In the face of conflicting evidence over the risks and benefits of routine prostate cancer screenings, a large, longitudinal analysis found Veterans Health Administration (VA) medical centers with lower prostate screening rates had higher rates of metastatic prostate cancer cases in subsequent years than centers with higher screening rates.
AI model using daily step counts predicts unplanned hospitalizations during cancer therapy
An artificial intelligence (AI) model developed by researchers can predict the likelihood that a patient may have an unplanned hospitalization during their radiation treatments for cancer. The machine-learning model uses daily step counts as a proxy to monitor patients’ health as they go through cancer therapy, offering clinicians a real-time method to provide personalized care. Findings will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.
Radiation therapy for high-risk, asymptomatic bone metastases may prevent pain and prolong life
Treating high-risk, asymptomatic bone metastases with radiation may reduce painful complications and hospitalizations and possibly extend overall survival in people whose cancer has spread to multiple sites, a phase II clinical trial suggests. Results of the multicenter, randomized trial (NCT03523351) will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.
FLASH radiation therapy shows promise in first-in-human trial
FLASH radiation treatment – which delivers therapeutic doses of radiation in a fraction of a second – may hold promise as a potential treatment for tough-to-kill tumors, a first-in-human study in a small number of people with bone cancer suggests.
Shortened course of radiation therapy safe and effective for men with high-risk prostate cancer
A new randomized study confirms that men with high-risk prostate cancer can be treated with five versus eight weeks of radiation therapy.
Allison Institute establishes internal advisory council of MD Anderson experts
MD Anderson’s James P. Allison institute today announced the establishment of its internal advisory council to provide scientific input and to align the work of the institute with the broader MD Anderson research enterprise.
MD Anderson hosts Leading Edge of Cancer Research Symposium
The University of Texas MD Anderson Cancer Center will host its virtual Leading Edge of Cancer Research Symposium from November 17-18, 2022, featuring presentations and discussions on important topics in discovery and translational research that will drive the next wave of cancer breakthroughs. The event also includes a virtual poster session; interested researchers are encouraged to submit abstracts by October 24, 2022.
U-M to lead multi-site $12M grant to study rare type of sarcoma
An international team of researchers led by the University of Michigan Rogel Cancer Center received a collaborative SPORE grant from the National Cancer Institute with a goal of bringing new insights into leiomyosarcoma, a rare form of cancer that seemingly originates in smooth muscle.
Three of the world’s top research institutions join forces to drive progress against pediatric cancer
Large-scale collaboration will leverage each institution’s expertise and infrastructure to advance understanding of the biological basis of pediatric cancers, identify new vulnerabilities of these diseases and accelerate cures globally.
Radiation oncology research and clinical trial results to be featured at ASTRO’s Annual Meeting in San Antonio
The American Society for Radiation Oncology (ASTRO) announced today the 10 studies that will be highlighted in the 2022 ASTRO Annual Meeting press program. Researchers will discuss their findings in two news briefings to be held October 24 and 25 in the Henry B. Gonzalez Convention Center in San Antonio and via live webcast. Reporters can register for the meeting at astro.org/annualmeetingpress.
Disarming the Body’s Defenders
Study shows how certain cancers neutralize T cells to subvert the immune system and help tumors grow
Machine learning creates opportunity for new personalized therapies
Researchers at the University of Michigan Rogel Cancer Center have developed a computational platform that can predict new and specific metabolic targets in ovarian cancer, suggesting opportunities to develop personalized therapies for patients that are informed by the genetic makeup of their tumors. The study appeared in Nature Metabolism.
$1.8 Million NIH Grant Supports Head and Neck Cancer Research
Sylvester Comprehensive Cancer Center researchers Lluis Morey, Ph.D., and Ramiro Verdun, Ph.D., have received a $1.8 million NIH R01 grant to study the epigenetic mechanisms that drive head and neck cancers.
Cancer Expert Shares Troubling Research on World Trade Center Exposure
Police officers and construction workers who responded on September 11, 2001, to the World Trade Center disaster in New York City and worked in its aftermath had at least twice the risk of developing the precursor for multiple myeloma compared…
Study suggests commonly used prostate cancer treatment rewires engine of prostate tumors
A new study from the University of Michigan Rogel Cancer Center suggests androgen receptor inhibitors can fundamentally rewire and reshape how prostate tumors function, and in certain cases even make them more aggressive. These findings will be published in Nature Communications on Sept. 15.
Three-drug combination slows progression of advanced kidney cancer
A targeted kinase inhibitor added to a two-drug immunotherapy combination slowed the progression of advanced kidney cancer in previously untreated patients, according to research led by an oncologist from Dana-Farber Cancer Institute.
New method eradicates deadly brain tumors by ‘starving’ them of energy source
Dramatic results in glioblastoma research: eliminating the astrocytes (a major class of brain cells) surrounding the tumors or inhibiting their ability to supply energy to the glioblastoma cells resulted in cancer cell death, and tumor regression within several days.
WORLD-RENOWNED CANCER EXPERT SHARES TROUBLING RESEARCH ON WORLD TRADE CENTER EXPOSURE
Miami, Fla. – September 11, 2001, changed America, and today we are learning more about the long-term health impacts of unprecedented environmental exposure to carcinogens at the World Trade Center disaster site. New research suggests that emergency response and recovery…
Cancer and HIV
Sylvester Comprehensive Cancer Center researcher Emmanuel Thomas, M.D., Ph.D., F.A.A.S.L.D., has been appointed to the National Institutes of Health’s (NIH) Coinfections and HIV Associated Cancers (HCAC) study section.
Department of Energy Announces $14.8 Million for Particle Accelerators for Science & Society
Today, the U.S. Department of Energy (DOE) announced $14.8 million in funding for advanced research projects in particle accelerator science and technology. Particle accelerators provide unique sources of light and particles that support the research of thousands of scientists worldwide, play a direct role in the production of more than $500 billion of goods annually, and treat more than 5 million cancer patients each year.
Icahn School of Medicine at Mount Sinai Announces Biomedical Laureates to Address Health Disparities in Environmental Health, Cancer, and Emergency Medicine
The Icahn School of Medicine at Mount Sinai announced today the appointment of three new Laureates as part of its Biomedical Laureates Program, furthering its institutional commitment to broadening diversity and mentorship opportunities.
Sexual dysfunction high among women with lung cancer
Sexual dysfunction is highly prevalent in women with lung cancer with most survey participants reporting little to no interest in sexual activity, according to research led by Narjust Florez (Duma), MD, associate director for the Cancer Care Equity Program at Dana-Farber Cancer Institute. The research was presented today at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer 2022.
Why do men face a higher risk of most types of cancer than women?
Rates of most types of cancer are higher in men than in women for reasons that are unclear.
Binghamton University, Upstate Medical agree to closer collaborations
A new agreement between Upstate Medical University and Binghamton University’s Thomas J. Watson College of Engineering and Applied Science will strengthen ties between the two schools and encourage closer research collaborations.
Study Shows Older Age and Smoking Most Important Risk Factors for Developing Any Cancer
A new large study led by researchers at the American Cancer Society shows older age and smoking are the two most important risk factors associated with a relative and absolute five-year risk of developing any cancer. The findings also demonstrate that in addition to age and smoking history, clinicians should consider excess body fatness, family history of any cancer, and several other factors that may help patients determine if they may benefit from enhanced cancer screening or prevention interventions. The data was published today in the journal Cancer.
New research could lead to simple blood test for brain tumours
Bristol-led research, published in the journal The Royal Society Interface, involved the development of mathematical models to assess the current use of biomarkers in the detection of GBMs and how such biomarker-based strategies can be improved.
Jianhua Zhao awarded $2.4M to reveal cancer targets through atomic-resolution imaging
Assistant Professor Jianhua Zhao, Ph.D., has been awarded a unique and competitive grant from the National Institute of General Medical Sciences (NIGMS), part of the National Institutes of Health (NIH). The five-year, $2.4 million grant aims to give researchers greater research flexibility to work on fundamental questions in biology.
New link found that connects cell signaling pathway to development of esophageal cancers, Barrett’s syndrome
A team of researchers at the Case Western Reserve University School of Medicine and Case Comprehensive Cancer Center believe they have identified a cell signaling pathway responsible for the development of esophageal adenocarcinomas, an aggressive form of esophageal cancer that has gradually become more common, even in younger people.
Researchers find link between genetic mutations and cancer treatment resistance
Patients with relapsed multiple myeloma are resistant to commonly used treatments. Researchers are one step closer to understanding the genetic reason why.
Cheryl Sampson Hired to Lead UNM Comprehensive Cancer Center’s Clinical Research Office
Cheryl Sampson has close to 25 years in health care research administration experience at both a university cancer center and in the health system setting. It gives her a unique combination of experience that suits the unique nature of the job in New Mexico.
Wistar Scientists Reveal New Function of Enzyme ADAR1 Linking it to Age-Related Diseases via a Role Independent of RNA-editing During Aging
Published today in Nature Cell Biology, Wistar scientists revealed a novel ADAR1-SIRT1-p16INK4a axis in regulating cellular senescence and its potential implications in tissue aging.
MD Anderson Research Highlights for July 13, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. Current advances include new targets involved in protecting DNA replication forks and preventing inflammatory responses, a new treatment option for elderly patients with late-stage acute myeloid leukemia, insights into the breast cancer tumor microenvironment, biomarkers of response to targeted and immune therapies, a novel cellular therapy option for osteosarcoma and a new target for inducing ferroptosis in cancer cells.
Sylvester Plays Pivotal Role in Practice-Changing Anal Cancer Prevention Study Published by NEJM
The New England Journal of Medicine (NEJM) has published the results of a study by Sylvester Comprehensive Cancer Center at the University of Miami Miller School and other investigators on anal cancer prevention in people living with HIV (PLHIV) that will likely establish a…
Unexpected link between most common cancer drivers may yield more effective drugs
Two of the most common genetic changes that cause cells to become cancerous, which were previously thought to be separate and regulated by different cellular signals, are working in concert, according to new research from the University of Wisconsin–Madison. To date, researchers have focused on finding drugs that block one or the other to treat cancer.
‘One Health’ Approach Is Necessary to Address Rising Environmental Causes of Childhood Cancers
A multi-disciplinary, “One Health” approach to cancer research is necessary to guide society in reduction of toxic substances, as well as regulation of chemical impacts on the environment and public health, according to an editorial published recently in Issue II of Annals of Research in Oncology.
Scientists discover cancer trigger that could spur targeted drug therapies
Researchers at the Department of Energy’s Oak Ridge National Laboratory have definitively linked the function of a specific domain of proteins important in plant-microbe biology to a cancer trigger in humans, knowledge that had eluded scientists for decades.
Could Carbon Monoxide Foam Help Fight Inflammation?
Carbon monoxide is best known as a potentially deadly gas. However, in small doses it also has beneficial qualities: It has been shown to reduce inflammation and can help stimulate tissue regeneration.
Department of Energy Awards 18 Million Node-Hours of Computing Time to Support Cutting-Edge Research
Today, the U.S. Department of Energy (DOE) announced that 18 million node-hours have been awarded to 45 scientific projects under the Advanced Scientific Computing Research (ASCR) Leadership Computing Challenge (ALCC) program. The projects, with applications ranging from advanced energy systems to climate change to cancer research, will use DOE supercomputers to uncover unique insights about scientific problems that would otherwise be impossible to solve using experimental approaches.
MD Anderson Research Highlights for June 29, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. Current advances include a lower-intensity therapy for acute myeloid leukemia, a new target for treating chronic myelomonocytic leukemia, real-world synthetic controls for clinical trials in rare cancers, a potential biomarker to predict endocrine therapy response in breast cancer, integrated CRISPR screens to identify novel tumor suppressors, and a deeper knowledge of the immune tumor microenvironment in melanoma-derived brain metastases.
Dynamic cells linked to brain tumor growth and recurrence
Tumors are made up of many types of cells, both cancerous and benign. The specific complexity of the cells inside brain tumors has been a trademark of the disease, one that makes treatment extremely difficult. While scientists have long known about the variety of cells within a brain tumor, the ways these tumors grow has relied on the understanding that the cells are static, unmoving and relatively fixed.
The Mark Foundation for Cancer Research Expands Partnership with The Johns Hopkins University to Accelerate Groundbreaking Immunotherapy Research
The Mark Foundation for Cancer Research and the Bloomberg~Kimmel Institute for Cancer Immunotherapy (BKI) announced today a new $10 million commitment at The Johns Hopkins University to fund novel work and advance immunotherapy research to provide lifesaving breakthroughs to people with cancer.
Brooke Emerling awarded $2.3 million to demystify breast cancer metabolism
Brooke Emerling from Sanford Burnham Prebys has been awarded a new grant from the National Institutes of Health (NIH) to continue her work on cellular signaling in cancer. The four-year, $2.3 million project could accelerate the development of new therapies for a range of cancers, particularly metastatic breast cancer. It also offers an answer to a longstanding mystery in cancer metabolism.
Getting Tough on Tuft Cell Lung Cancer
Cold Spring Harbor Laboratory (CSHL) Professor Christopher Vakoc’s team discovered in 2018 a new type of small-cell lung cancer. The cancer originates from cells known as tuft cells.